AN 8-WEEK OPEN TRIAL OF DESVENLAFAXINE, A NOVEL SEROTONIN AND NOREPINEPHRINE INHIBITOR, FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN PERIMENOPAUSAL WOMEN: EFFECTS ON MOOD, COGNITION, BRAIN FUNCTION, AND QUALITY OF LIFE Grant